TVM Capital Life Science

Egg Medical, Inc. is a medical device manufacturer based in Arden Hills, Minnesota, established in 2014. The company specializes in healthcare equipment designed to enhance safety during medical procedures that involve real-time imaging. Its flagship product, EGGNEST, is a cath lab patient table that significantly reduces scatter radiation exposure for both patients and healthcare professionals, including physicians, surgeons, nurses, and technicians. This innovative system is built on a carbon fiber sled base, which not only diminishes radiation exposure but also integrates antimicrobial properties to further protect users. EGGNEST aims to provide a safe and efficient work environment, allowing medical professionals to perform critical diagnostic and therapeutic procedures without disrupting workflow.

Neurocare Group is dedicated to enhancing mental health and performance through personalized therapy solutions. The company develops integrated equipment and a digital therapy platform that empowers clinicians to provide tailored treatment plans based on comprehensive assessments. By incorporating factors such as brain activity, sleep patterns, biomarkers, and other lifestyle metrics, Neurocare's platform facilitates individualized therapeutic programs. This approach leverages the principles of neuroplasticity, offering patients a measurable and effective clinical experience that supports their mental health needs. Through its innovative solutions, Neurocare aims to deliver best practices in neuroscience applications, contributing to improved mental well-being and performance.

DEBx Medical is a pioneering medical technology company dedicated to advancing wound care solutions, particularly for chronic and hard-to-heal wounds. The company focuses on addressing critical challenges such as infection and biofilm removal to enhance the wound healing process. DEBx Medical provides a comprehensive approach that includes diagnosis, treatment, follow-up care, and maintenance of healthy wound beds. By enabling healthcare providers to implement effective and affordable treatments in everyday clinical practice, DEBx Medical aims to significantly improve patient outcomes and quality of life for those suffering from chronic wounds.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through advanced nanotechnology. The company develops a pipeline of improved drug products aimed at increasing the bioavailability of poorly water-soluble medicines. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates both polymeric and crystalline nanoparticles, which provide significant differentiation and added benefits for patients. The company also offers services that support pre-clinical and clinical-stage formulations for clients’ new chemical entities or established branded drugs, facilitating access to next-generation nano-formulated therapies that aim to improve patient outcomes.

Boston Oncology is dedicated to enhancing healthcare in emerging markets by facilitating the local development and production of licensed biopharmaceutical products. The company focuses on manufacturing specialty generic small-molecule and biotechnology therapies, which enables developing nations to access critical oncology treatments at reduced costs. By providing necessary resources and capital, Boston Oncology assists clients in building and managing a diverse portfolio of pharmaceutical products while establishing local manufacturing facilities in targeted regions. This approach not only supports the health and prosperity of these nations but also ensures that essential therapies are more accessible to their populations.

Neurocare Group is dedicated to enhancing mental health and performance through personalized therapy solutions. The company develops integrated equipment and a digital therapy platform that empowers clinicians to provide tailored treatment plans based on comprehensive assessments. By incorporating factors such as brain activity, sleep patterns, biomarkers, and other lifestyle metrics, Neurocare's platform facilitates individualized therapeutic programs. This approach leverages the principles of neuroplasticity, offering patients a measurable and effective clinical experience that supports their mental health needs. Through its innovative solutions, Neurocare aims to deliver best practices in neuroscience applications, contributing to improved mental well-being and performance.

Smart Reporting GmbH is a Munich-based company that specializes in providing a digital health solution for structured medical reporting, particularly in the fields of radiology and pathology. Established in 2014, the company offers an online platform that enables radiologists to generate high-quality medical reports through intelligent software that adheres to guideline-compliant criteria. The platform facilitates the creation of report templates, automatic text suggestions, and integration with hospital systems, thereby enhancing the efficiency and quality of medical reporting. Additionally, Smart Reporting provides tools for hospitals and practices to implement reporting standards, optimize templates, and ensure consistent report appearance across various physicians. The company also supports medical registries and clinical studies with solutions for structured reporting, data collection, and multilingual capabilities, all aimed at improving communication and quality assurance in medical documentation.

Vektor Medical, based in San Diego, focuses on enhancing the treatment of atrial fibrillation and other arrhythmias through its innovative technology. The company has developed vMap, an AI-based, non-invasive system that analyzes arrhythmia using a patient's electrocardiogram (ECG) to pinpoint the sources of abnormal heart rhythms. This FDA-cleared solution aims to enhance cardiac ablation outcomes, streamline workflows, and boost procedural efficiency for healthcare professionals.

Myo is a communication platform specifically designed for the elderly care sector. The company focuses on enhancing interactions among elderly individuals, their families, and caregivers by providing a user-friendly interface that incorporates traditional messaging features alongside transactional services. This platform facilitates the sharing of photos, videos, texts, and voice messages, allowing caregivers to communicate securely and professionally with relatives. Myo aims to improve the quality of care by fostering closer connections and enhancing communication within the care community. The company is also committed to expanding its team with talented individuals who are passionate about developing products that contribute to better care solutions.

DEBx Medical is a pioneering medical technology company dedicated to advancing wound care solutions, particularly for chronic and hard-to-heal wounds. The company focuses on addressing critical challenges such as infection and biofilm removal to enhance the wound healing process. DEBx Medical provides a comprehensive approach that includes diagnosis, treatment, follow-up care, and maintenance of healthy wound beds. By enabling healthcare providers to implement effective and affordable treatments in everyday clinical practice, DEBx Medical aims to significantly improve patient outcomes and quality of life for those suffering from chronic wounds.

Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.

Recurv Pharma's RP-001 is a novel chemical entity (NCE) that is administered in a nano-emulsion formulation, concentrating medication delivery to the tumour while preserving healthy organs. Strong efficacy in a variety of pre-clinical tumour models, including non-small cell lung, breast, ovarian, prostate, pancreatic, and colorectal cancers, has allowed the chemical to show that it can destroy tumours even in multi-drug resistant tumours.

AMILI is a biotechnology company focused on advancing gut microbiome research to address significant healthcare needs. The company develops diagnostic tests, predictive algorithms, and microbiome-modifying interventions, including probiotics and fecal microbiota transplants, to assist in the treatment of bacterial infections. By collecting gut microbiome samples, AMILI aims to enhance its understanding of microbiota and advance treatment options for patients coping with infections and other health conditions. Their innovative approach to microbiome science seeks to improve human health by identifying and utilizing beneficial microbes.

Egg Medical, Inc. is a medical device manufacturer based in Arden Hills, Minnesota, established in 2014. The company specializes in healthcare equipment designed to enhance safety during medical procedures that involve real-time imaging. Its flagship product, EGGNEST, is a cath lab patient table that significantly reduces scatter radiation exposure for both patients and healthcare professionals, including physicians, surgeons, nurses, and technicians. This innovative system is built on a carbon fiber sled base, which not only diminishes radiation exposure but also integrates antimicrobial properties to further protect users. EGGNEST aims to provide a safe and efficient work environment, allowing medical professionals to perform critical diagnostic and therapeutic procedures without disrupting workflow.

Centogene is a prominent genetic biotech company specializing in the diagnosis and analysis of rare inherited diseases. Headquartered in Rostock, Germany, with additional operations in Berlin and Cambridge, Massachusetts, Centogene focuses on transforming clinical, genetic, and biochemical data into actionable medical solutions. The company serves a diverse global patient population and aims to enhance awareness and understanding of rare diseases across various ethnicities. Centogene operates in two main segments: diagnostics, which offers targeted genetic sequencing and diagnostic services, and pharmaceuticals, which collaborates with partners to provide services such as patient recruitment, biomarker discovery, and epidemiological insights. Through its comprehensive approach, Centogene is dedicated to advancing the field of human genetics and improving the lives of patients and their families affected by rare diseases.

Access Vascular, Inc. is a medical technology company based in Bedford, Massachusetts, founded in 2015. The company specializes in developing innovative venous access devices that utilize advanced hydrogel materials to significantly reduce thrombosis accumulation, a common complication in intravenous therapy. Their product line includes peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. By addressing critical issues such as occlusions and infections, Access Vascular aims to enhance clinical outcomes, lower healthcare costs, and improve patient experiences. The company's HydroPICC catheter exemplifies their commitment to advancing venous access technology, as it offers superior performance over existing solutions, thereby increasing catheter dwell time and minimizing associated complications.

Kent Imaging Inc. is a medical device company based in Calgary, Canada, founded in 2006. The company specializes in the development and commercialization of multispectral oxygenation imaging technology aimed at improving patient outcomes in various medical fields, including plastic surgery, trauma care, wound management, and cardiac specialties. Kent Imaging's innovative imaging systems provide a non-invasive method for assessing tissue oxygen saturation, assisting physicians in evaluating compromised tissue without the need for contact or injected dyes. With multiple patents in medical technology, Kent Imaging is dedicated to delivering practical solutions that enhance decision-making in healthcare settings. In addition to its headquarters in Calgary, the company operates locations in Chicago, Los Angeles, Salt Lake City, and Seattle.

Vespina Lifesciences plans to develop to proof-of-concept a potential compound with the potential to treat certain types of inflammatory diseases including pulmonary indications with poor therapeutic options as well as non-pulmonary inflammatory diseases. The compound was originally discovered and characterized at Denmark-based Neuprozyme Therapeutics ApS. There are upwards of 70,000 patients newly diagnosed with bronchiectasis in the US every year as more than half of the 16+ million patients diagnosed with COPD in the US likely also have concurrent bronchiectasis. There are no approved treatments that specifically address the underlying mechanism of disease.

ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and Crohn’s disease. The company's antibody targets a new critical target in chronic inflammation and auto-immunity which was originally discovered by Dr. Tessier in Canada.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through advanced nanotechnology. The company develops a pipeline of improved drug products aimed at increasing the bioavailability of poorly water-soluble medicines. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates both polymeric and crystalline nanoparticles, which provide significant differentiation and added benefits for patients. The company also offers services that support pre-clinical and clinical-stage formulations for clients’ new chemical entities or established branded drugs, facilitating access to next-generation nano-formulated therapies that aim to improve patient outcomes.

Emovi specializes in advanced knee joint assessment technologies aimed at improving patient quality of life. The company has developed a device that serves as a diagnostic aid for knee injuries and osteoarthritis, providing medical professionals with actionable data on joint movement while weight-bearing. This technology helps in reducing pain, minimizing opioid use, and shortening recovery times for patients. Emovi's commitment to innovation in healthcare is reflected in its focus on delivering high-quality products that enhance the treatment and management of knee conditions.

Acer Therapeutics Inc. is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Founded in 2013 and headquartered in Newton, Massachusetts, the company has a diverse clinical pipeline that includes several promising candidates. EDSIVO is designed for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation. ACER-001, a taste-masked formulation of sodium phenylbutyrate, targets various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. Additionally, Acer is developing osanetant for the treatment of induced vasomotor symptoms and has initiated research on emetine hydrochloride as a potential COVID-19 treatment in collaboration with the National Center for Advancing Translational Sciences. The company also holds a license agreement with Sanofi for worldwide rights to osanetant.

Panthera Dental Inc. is a Québec-based company that specializes in designing, developing, manufacturing, and marketing innovative dental restoration solutions and dental sleep appliances. Founded in 2011 by brothers Gabriel and Bernard Robichaud, the company has established itself as a leader in prosthetic implant solutions. Its product offerings include Angulated Screw Channels, Metal Implant Bars, and a variety of implant bridges such as Diamart and Integrated Bars, which enhance rigidity and ease of cleaning. Additionally, Panthera Dental provides dental appliances like D-SAD for the treatment of snoring, as well as specialized products for complex cases. With a commitment to improving patient quality of life, the company employs over 50 individuals and maintains an office in New Jersey.

Centogene is a prominent genetic biotech company specializing in the diagnosis and analysis of rare inherited diseases. Headquartered in Rostock, Germany, with additional operations in Berlin and Cambridge, Massachusetts, Centogene focuses on transforming clinical, genetic, and biochemical data into actionable medical solutions. The company serves a diverse global patient population and aims to enhance awareness and understanding of rare diseases across various ethnicities. Centogene operates in two main segments: diagnostics, which offers targeted genetic sequencing and diagnostic services, and pharmaceuticals, which collaborates with partners to provide services such as patient recruitment, biomarker discovery, and epidemiological insights. Through its comprehensive approach, Centogene is dedicated to advancing the field of human genetics and improving the lives of patients and their families affected by rare diseases.

AL-S Pharma AG develops AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of ALS.

Ixchelsis Ltd is a clinical-stage biotechnology company headquartered in Sandwich, United Kingdom, founded in 2011. The firm is focused on the development of IX-01, an oxytocin receptor antagonist aimed at treating premature ejaculation (PE). This innovative therapeutic approach represents a promising advancement in male sexual health. IX-01 has successfully completed a Phase 1 single ascending dose study in healthy male volunteers and is currently advancing toward clinical proof of concept. The company is supported by funding from prominent investors and is led by a skilled management team with significant experience in pharmaceutical research and development, particularly in the field of male reproductive health.

AurKa Pharma is a biopharmaceutical company focused on developing a single compound aimed at treating solid tumors. The company has completed GLP toxicology studies for its drug candidate and is preparing to initiate clinical development. Once it receives the necessary regulatory approvals, the compound will be tested in clinical settings to determine its efficacy in treating solid tumors. AurKa Pharma intends to explore additional cancer indications after establishing proof-of-concept, ultimately aiming to enhance treatment options for cancer patients.

Acer Therapeutics Inc. is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Founded in 2013 and headquartered in Newton, Massachusetts, the company has a diverse clinical pipeline that includes several promising candidates. EDSIVO is designed for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation. ACER-001, a taste-masked formulation of sodium phenylbutyrate, targets various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. Additionally, Acer is developing osanetant for the treatment of induced vasomotor symptoms and has initiated research on emetine hydrochloride as a potential COVID-19 treatment in collaboration with the National Center for Advancing Translational Sciences. The company also holds a license agreement with Sanofi for worldwide rights to osanetant.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through advanced nanotechnology. The company develops a pipeline of improved drug products aimed at increasing the bioavailability of poorly water-soluble medicines. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates both polymeric and crystalline nanoparticles, which provide significant differentiation and added benefits for patients. The company also offers services that support pre-clinical and clinical-stage formulations for clients’ new chemical entities or established branded drugs, facilitating access to next-generation nano-formulated therapies that aim to improve patient outcomes.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Esperas Pharma is a special purpose company created to develop one compound to proof-of-concept.

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

Definiens is a provider of image analysis and data mining solutions specifically designed for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. The company's software delivers detailed insights from whole tissue slides, cell-based assays, and full body scans, enabling the integration of this information with data from various sources. By automating analysis workflows, Definiens enhances the capabilities of pharmaceutical and biotechnology companies, research institutions, clinical service organizations, and pathologists, facilitating informed decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, with additional offices in the United States, Definiens aims to advance research, contribute to the development of personalized medicine, and improve patient outcomes.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Invendo Medical GmbH is a developer and manufacturer of sterile, single-use, robotically-assisted high-definition endoscopy products specifically designed for gastroenterology and gastrointestinal surgery. The company's flagship product, the invendoscopy E200 System, comprises a sterile colonoscope, a handheld control unit, and a supply and processing unit, providing a comprehensive solution for healthcare providers in the United States and Europe. Founded in 2001 and headquartered in Weinheim, Germany, Invendo Medical aims to enhance patient compliance and increase the number of gastroenterological procedures through innovative design and technology. The company, previously known as STM Medizintechnik GmbH, rebranded in 2006 and operates as a subsidiary of Ambu A/S. Invendo Medical focuses on developing highly flexible and easy-to-use endoscopy products, addressing the challenges associated with traditional gastrointestinal endoscopy methods.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, that specialized in the development of individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 1997 and formerly known as Merix Bioscience, the company utilized its proprietary Arcelis technology platform to create personalized treatments. Its notable product candidates included rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, aimed at treating human immunodeficiency virus in Phase II trials. Other investigational products included treatments for transplant rejection and autoimmune diseases. However, Argos Therapeutics filed for Chapter 7 bankruptcy and ceased operations on September 24, 2019.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

Ixchelsis Ltd is a clinical-stage biotechnology company headquartered in Sandwich, United Kingdom, founded in 2011. The firm is focused on the development of IX-01, an oxytocin receptor antagonist aimed at treating premature ejaculation (PE). This innovative therapeutic approach represents a promising advancement in male sexual health. IX-01 has successfully completed a Phase 1 single ascending dose study in healthy male volunteers and is currently advancing toward clinical proof of concept. The company is supported by funding from prominent investors and is led by a skilled management team with significant experience in pharmaceutical research and development, particularly in the field of male reproductive health.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Definiens is a provider of image analysis and data mining solutions specifically designed for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. The company's software delivers detailed insights from whole tissue slides, cell-based assays, and full body scans, enabling the integration of this information with data from various sources. By automating analysis workflows, Definiens enhances the capabilities of pharmaceutical and biotechnology companies, research institutions, clinical service organizations, and pathologists, facilitating informed decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, with additional offices in the United States, Definiens aims to advance research, contribute to the development of personalized medicine, and improve patient outcomes.

Manzil Healthcare Services specializes in delivering a wide range of individualized home care services aimed at enhancing the quality of life for patients. Their offerings include physiotherapy, elder care, mother and baby care, lactation consultation, and pediatric care, as well as specialized services like ventilation support and post-operative care. By providing technology-enabled, multidisciplinary care in the comfort of patients' homes, Manzil Healthcare Services supports both adult and pediatric patients in their health management needs, including wound care and diabetes management. This approach not only facilitates easier access to essential healthcare services but also fosters a supportive environment for recovery and well-being.

Cambridge Medical and Rehabilitation Center is a leading provider of post-acute care and rehabilitation services in the MENA region, focusing on individuals recovering from serious injuries or illnesses. The center is dedicated to restoring hope and ensuring a continuum of care for patients and their families. By integrating modern technology with the expertise of physicians, physiotherapists, and speech and language pathologists, Cambridge Medical and Rehabilitation Center offers personalized treatment plans that include physical therapy, occupational therapy, speech-language therapy, hydrotherapy, and respiratory therapy. This comprehensive approach aims to enhance the health and independence of individuals affected by neurological issues, facilitating their return home either independently or with family support and home health services.

Amecath is a manufacturer and global distributor of medical products, specializing in catheter kits and supplies across urology, venous access, and dialysis. The company is involved in the design, development, and production of various types of catheters, including dialysis catheters, urological catheters, central venous catheters, pediatric catheters, and percutaneous sheath introducers. Amecath's products are protected by intellectual property rights and are sold in Egypt, as well as exported to multiple international markets.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, that specialized in the development of individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 1997 and formerly known as Merix Bioscience, the company utilized its proprietary Arcelis technology platform to create personalized treatments. Its notable product candidates included rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, aimed at treating human immunodeficiency virus in Phase II trials. Other investigational products included treatments for transplant rejection and autoimmune diseases. However, Argos Therapeutics filed for Chapter 7 bankruptcy and ceased operations on September 24, 2019.

Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

Cambridge Broadband Networks Limited, established in 1999 and based in Cambridge, United Kingdom, specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers globally. The company’s flagship product, VectaStar, is a multipoint microwave platform that offers mobile backhaul and enterprise access solutions, including VectaStar Gigabit for macro backhaul and VectaStar Metro for multipoint microwave backhaul. Additionally, VectaStar includes a Radio Controller for enhanced network performance. Cambridge Broadband also provides a comprehensive network management system and various applications to assist with equipment configuration and optimization. The company offers extensive consultancy, training, and support services, allowing network operators to effectively design and implement microwave backhaul networks. By delivering high-quality equipment and services, Cambridge Broadband aims to enhance networking capability and efficiency to address the demands of increasing mobile data traffic.

Anchor Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the design and development of peptide modulators for G protein-coupled receptors (GPCRs). The company utilizes its proprietary Pepducin technology platform to create lipopeptide drug candidates that target intracellular domains of GPCRs, allowing for the allosteric modulation of GPCR signaling. Anchor Therapeutics aims to develop innovative treatment options for serious medical conditions, including cancer, inflammation, metabolic diseases, heart disease, and pain. Its pipeline includes internal programs addressing critical indications such as regenerative medicine and diabetes. Founded in 2006 and previously known as Ascent Therapeutics, Inc., Anchor Therapeutics continues to advance its research in the field of GPCR-targeted therapeutics.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Bourn Hall is a leading provider of fertility and in vitro fertilization services based in Cambridge, United Kingdom, with additional clinics in Colchester, Norwich, and Wickford. Established by IVF pioneers Steptoe and Edwards, Bourn Hall made history as the first clinic in the world to offer IVF treatments. The clinic caters to both self-funding and NHS patients, providing a safe and supportive environment to address fertility-related issues for both men and women. With a commitment to helping individuals and couples achieve their dreams of parenthood, Bourn Hall has successfully assisted in the conception of over 13,000 children, earning a reputation as a sanctuary for those facing difficulties conceiving.

Helomics Corporation is a personalized healthcare company based in Pittsburgh, Pennsylvania, focused on enhancing cancer care through a range of innovative diagnostic products and services. The company has developed the Precision Cellular Analytical Platform, which analyzes cell cycle and proliferation data over a 25-35 day period. Helomics' offerings include ChemoFx, which assists in selecting effective treatments for gynecologic cancer, and BioSpeciFx, a set of biomarker tests that provide insights into tumor characteristics and potential drug responses. Additionally, Helomics provides GeneFx Colon and GeneFx Lung, microarray-based gene signatures tailored for patients with stage two colon cancer and early-stage non-small cell lung cancer, respectively. The company also engages in tumor profiling services, including bioinformatics and contract research, to support clinical decision-making. Furthermore, Helomics utilizes its D-CHIP digital clinical health insight platform to deliver personalized oncology roadmaps and collaborates with pharmaceutical and diagnostics companies to enhance patient selection for clinical trials. Founded in 1995 and formerly known as Precision Therapeutics, Helomics continues to push the boundaries of precision oncology.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading products, NOX-A12 and NOX-E36, classified as Spiegelmers. This innovative class of drugs offers specific advantages over traditional therapies, aiming to improve the effectiveness of cancer treatments. TME Pharma has also established a strategic alliance with Pfizer, Inc. The company is headquartered in Berlin, Germany, and is dedicated to advancing its research to benefit patients battling cancer.

Direvo Industrial Biotechnology GmbH is a privately owned company based in Cologne, Germany, specializing in the development and marketing of biology-based products and processes for non-pharmaceutical applications. Founded in 2008, the company utilizes its expertise in enzymes, microbes, and process optimization to create bio-based solutions across various sectors, including clean energy, clean chemistry, and biomass conversion. Direvo offers a range of innovative platforms, such as the BluZy portfolio, designed for the grain ethanol industry, which includes products that enhance the nutritional value of bio-ethanol by-products and improve process efficiency in ethanol production. Additionally, the company provides the BluServ platform, focused on automated high-throughput screening for protein and strain engineering, and the BluCon technology platform, which converts non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with global leaders in the industry to deliver customized solutions tailored to specific market needs.

VPIsystems, originally established as VPI Virtual Photonics in 1997, specializes in developing and marketing network planning software and services tailored for the telecommunications industry, both in the United States and globally. The company's offerings include Photonic Design Automation, which aids in the modeling and optimization of photonic components and subsystems, and OnePlan, an integrated system that facilitates the design and implementation of transitions to IP-based networks for communications service providers, systems integrators, and manufacturers. VPIsystems aims to enhance the efficiency of network planning and engineering processes through predictive network analytics and comprehensive data integration, thereby improving network reliability and supporting informed technology decisions. The company maintains strategic partnerships with prominent firms such as Accenture and HP and is headquartered in Holmdel, New Jersey, with additional offices across Europe, Asia, and Australia. In July 2001, the company rebranded itself as VPIsystems, Inc.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

ProVita International Medical Center, based in Abu Dhabi, United Arab Emirates, operates healthcare facilities that specialize in post-acute care and rehabilitation services. Founded in 1995, ProVita provides a wide range of services, including nursing, respiratory therapy, physiotherapy, occupational therapy, speech therapy, and nutritional services, catering particularly to ventilator-dependent residents. The center is notable for its multicultural environment, employing around 300 internationally trained staff who adhere to high global nursing standards, ensuring comprehensive care for patients. ProVita has established itself as a leader in providing patient-centric care, contributing to its reputation as a pioneering facility in the region.

Direvo Industrial Biotechnology GmbH is a privately owned company based in Cologne, Germany, specializing in the development and marketing of biology-based products and processes for non-pharmaceutical applications. Founded in 2008, the company utilizes its expertise in enzymes, microbes, and process optimization to create bio-based solutions across various sectors, including clean energy, clean chemistry, and biomass conversion. Direvo offers a range of innovative platforms, such as the BluZy portfolio, designed for the grain ethanol industry, which includes products that enhance the nutritional value of bio-ethanol by-products and improve process efficiency in ethanol production. Additionally, the company provides the BluServ platform, focused on automated high-throughput screening for protein and strain engineering, and the BluCon technology platform, which converts non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with global leaders in the industry to deliver customized solutions tailored to specific market needs.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

Arteris specializes in designing and distributing intellectual property (IP) for Network-on-Chip (NoC) interconnect technology, primarily serving the System-on-Chip (SoC) market. Its core products include NoC IP and SoC integration automation software, enabling customers to enhance product performance while reducing power consumption and accelerating time-to-market. Arteris operates globally, with a significant portion of its profits originating from the Asia Pacific region.

Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

Ubidyne is a technology company founded in 2005, specializing in digital active antenna technology. The company’s innovative Antenna Embedded Radio technology integrates micro-radio systems within wireless antennas, revolutionizing mobile communications by eliminating the need for coaxial feeder cables, remote electrical tilt, and additional amplifiers. Ubidyne's products are designed to support a wide range of mobile communication standards, including GSM, UMTS, HSPA+, and LTE, and are compatible with both CPRI and OBSAI optical interfaces. This advanced technology enables efficient deployment of multi-standard wireless services, enhancing coverage, capacity, and energy efficiency of mobile networks globally. Ubidyne's solutions cater to various applications, from pico cells to smart macro cells and distributed in-building systems.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Cambridge Broadband Networks Limited, established in 1999 and based in Cambridge, United Kingdom, specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers globally. The company’s flagship product, VectaStar, is a multipoint microwave platform that offers mobile backhaul and enterprise access solutions, including VectaStar Gigabit for macro backhaul and VectaStar Metro for multipoint microwave backhaul. Additionally, VectaStar includes a Radio Controller for enhanced network performance. Cambridge Broadband also provides a comprehensive network management system and various applications to assist with equipment configuration and optimization. The company offers extensive consultancy, training, and support services, allowing network operators to effectively design and implement microwave backhaul networks. By delivering high-quality equipment and services, Cambridge Broadband aims to enhance networking capability and efficiency to address the demands of increasing mobile data traffic.

ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.

ExtendMedia specializes in software and media services that assist content providers and distributors in creating, delivering, managing, and monetizing online content across various devices. The company's flagship product, OpenCASE, serves as a robust foundation for digital media businesses, enabling efficient integration with existing systems and automating large-scale content delivery processes. With over 16 years of experience, ExtendMedia has collaborated with leading communications and media companies, embedding its extensive industry knowledge into OpenCASE. This software not only enhances operational efficiency but also supports diverse business models, making it a valuable tool for media companies and network operators managing digital video content.

Silicon Hive BV is a Netherlands-based company established in 2003, specializing in the supply of semiconductor intellectual properties (IP). It designs, builds, and licenses application-specific system solutions tailored for consumer electronics and mobile terminal applications, serving both semiconductor manufacturers and original equipment manufacturers. The company's offerings include processor cores, development tools, and application libraries, enabling clients to create programmable integrated circuits for imaging, video, and wireless communication applications. With offices in Eindhoven (Netherlands), San Jose (USA), Tokyo (Japan), Seoul (South Korea), and Bangalore (India), Silicon Hive operates independently since 2007.

CommProve, established in 1996, specializes in real-time Quality of Service (QoS) monitoring for wireless networks. The company, founded by experts in network operations and software engineering, offers a platform that collects, analyzes, and integrates network usage data from various mobile networks. This enables mobile network operators to gain real-time insights into their operations, helping them control financial performance, quality of experience, and network performance.

SpePharm is a European specialty pharmaceutical company focused on acquiring, registering, and marketing high-value medicines primarily for the hospital market. The company specializes in oncology, hematology, and supportive care, offering medical products that aid in the local oral treatment and management of complications arising from radiotherapy or chemotherapy. SpePharm's management team possesses extensive global experience in the pharmaceutical sector, with a strong understanding of the European regulatory environment and a particular expertise in niche and orphan products. This strategic focus allows SpePharm to effectively address the needs of healthcare professionals and patients across Europe.

Since its inception, BitWave has been dedicated to the development of a universal programmable transceiver, the Softransceiver RFIC. The technology will allow wireless carriers and cell phone manufacturers to deploy more services and devices in less time with additional functionality.

Vivendy Therapeutics Ltd. is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative treatments for rare lysosomal storage diseases. Founded in 2006, the company is primarily engaged in creating an enzyme replacement therapy for Morbus Morquio, also known as MPS IVA, which is caused by a deficiency in a specific enzyme. Vivendy has developed a recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that has been specifically modified to enhance enzyme activity, significantly improving the efficacy of the therapy. Through its research and development efforts, Vivendy Therapeutics aims to address the unmet medical needs of patients suffering from this rare condition.

Arteris specializes in designing and distributing intellectual property (IP) for Network-on-Chip (NoC) interconnect technology, primarily serving the System-on-Chip (SoC) market. Its core products include NoC IP and SoC integration automation software, enabling customers to enhance product performance while reducing power consumption and accelerating time-to-market. Arteris operates globally, with a significant portion of its profits originating from the Asia Pacific region.

Winbox Technologies specializes in connected TV solutions tailored for original equipment manufacturers and service providers. The company offers a range of hardware and software products that streamline the development of IPTV receivers, video-on-demand systems, hard disk video recorders, connected TVs, and set-top boxes. By providing comprehensive "TurnKey" solutions, which include all necessary components such as hardware, software, and production services, Winbox Technologies allows customers to minimize development time and investment. Additionally, clients have the option to license specific technology modules for in-house development, further enhancing flexibility and efficiency in their product offerings.

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drugs to treat autoimmune and central nervous system disorders. The company employs a unique precision deuterium chemistry platform to modify the properties of validated drug molecules, resulting in a diverse pipeline of new chemical entities. Key product candidates include CTP-543, which is in Phase III trials for alopecia areata, and CTP-692, undergoing Phase II trials for schizophrenia. Additionally, AVP-786, a combination therapy for neurologic and psychiatric disorders, is also in Phase III trials. Concert Pharmaceuticals aims to enhance drug safety and efficacy while minimizing research and development risks and costs. Established in 2006 and based in Lexington, Massachusetts, the company has formed strategic collaborations with several pharmaceutical partners to advance its innovative drug development efforts.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

CoreOptics is a prominent manufacturer of advanced subsystems designed for high-speed optical networking applications in the telecommunications and information technology sectors. The company specializes in 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, catering to Metro, Regional, and Long Haul optical and data networking markets. CoreOptics advocates for open systems in optical communications networks, enabling efficient data transmission regardless of data rates or fiber types. Their innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is the only field-proven solution available, empowering Tier 1 systems vendors and carriers to enhance their high-performance networks using existing fiber infrastructure. By eliminating the need for Optical Compensators and associated Second Stage Amplifiers, CoreOptics' products can significantly reduce initial deployment costs for customers, making them a valuable partner in the evolution of optical networking.

Albireo Pharma, Inc. is a biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative bile acid modulators aimed at treating rare pediatric liver diseases and gastrointestinal disorders. The company's lead product candidate, odevixibat, is an ileal bile acid transporter inhibitor currently undergoing phase III clinical trials for the treatment of progressive familial intrahepatic cholestasis, biliary atresia, alagille syndrome, and other cholestatic liver diseases. Additionally, Albireo is advancing Elobixibat, which targets chronic constipation and other functional gastrointestinal disorders, as well as nonalcoholic steatohepatitis. The company is also developing A3384 for gastrointestinal diseases and has established a licensing agreement with EA Pharma for the development and commercialization of elobixibat.

RIEMSER Pharma GmbH, based in Greifswald, is an international specialty pharmaceutical company dedicated to addressing high unmet medical needs in therapeutic niche areas. The company specializes in the distribution and life cycle management of pharmaceuticals, with core competencies in oncology, anti-infectives, and dermatology. With a strong emphasis on innovation and patient care, RIEMSER Pharma leverages its extensive expertise to enhance the availability and effectiveness of its products in these critical therapeutic fields.

Vivendy Therapeutics Ltd. is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative treatments for rare lysosomal storage diseases. Founded in 2006, the company is primarily engaged in creating an enzyme replacement therapy for Morbus Morquio, also known as MPS IVA, which is caused by a deficiency in a specific enzyme. Vivendy has developed a recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that has been specifically modified to enhance enzyme activity, significantly improving the efficacy of the therapy. Through its research and development efforts, Vivendy Therapeutics aims to address the unmet medical needs of patients suffering from this rare condition.

Enigma Semiconductor specializes in developing advanced silicon solutions aimed at enhancing wired communications. The company focuses on creating innovative components and subsystems tailored for various applications, including Metropolitan and Access Networks, enterprise and internet infrastructure, and storage systems. Enigma's offerings include semiconductors designed for switching systems and high-speed line card and backplane systems, supporting link speeds of up to 6.25G and line card speeds of up to 1x40G. The team behind Enigma comprises seasoned professionals with backgrounds in prominent technology companies, bringing a wealth of industry experience to its operations.

Ascent Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, metabolic CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets.

Direvo Industrial Biotechnology GmbH is a privately owned company based in Cologne, Germany, specializing in the development and marketing of biology-based products and processes for non-pharmaceutical applications. Founded in 2008, the company utilizes its expertise in enzymes, microbes, and process optimization to create bio-based solutions across various sectors, including clean energy, clean chemistry, and biomass conversion. Direvo offers a range of innovative platforms, such as the BluZy portfolio, designed for the grain ethanol industry, which includes products that enhance the nutritional value of bio-ethanol by-products and improve process efficiency in ethanol production. Additionally, the company provides the BluServ platform, focused on automated high-throughput screening for protein and strain engineering, and the BluCon technology platform, which converts non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with global leaders in the industry to deliver customized solutions tailored to specific market needs.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Arteris specializes in designing and distributing intellectual property (IP) for Network-on-Chip (NoC) interconnect technology, primarily serving the System-on-Chip (SoC) market. Its core products include NoC IP and SoC integration automation software, enabling customers to enhance product performance while reducing power consumption and accelerating time-to-market. Arteris operates globally, with a significant portion of its profits originating from the Asia Pacific region.

Netviewer GmbH is a company that specializes in web conferencing solutions, enabling users to collaboratively view and edit documents over the Internet. Founded in 2001 and headquartered in Karlsruhe, Germany, the company offers a range of products including Netviewer Meet for online meetings, Netviewer Support for customer assistance, and Netviewer Admin for administrative tasks. Its services cater to various applications such as project collaborations, live demonstrations, training, and webinars aimed at enhancing customer engagement and loyalty. Netviewer provides its offerings as software-as-a-service, allowing flexibility and accessibility for users. The company also maintains subsidiary operations in several countries, including Switzerland, France, the United Kingdom, the United States, the Netherlands, Austria, Italy, Spain, Poland, and Sweden, further extending its reach in the web conferencing market.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading products, NOX-A12 and NOX-E36, classified as Spiegelmers. This innovative class of drugs offers specific advantages over traditional therapies, aiming to improve the effectiveness of cancer treatments. TME Pharma has also established a strategic alliance with Pfizer, Inc. The company is headquartered in Berlin, Germany, and is dedicated to advancing its research to benefit patients battling cancer.

Silicon Hive BV is a Netherlands-based company established in 2003, specializing in the supply of semiconductor intellectual properties (IP). It designs, builds, and licenses application-specific system solutions tailored for consumer electronics and mobile terminal applications, serving both semiconductor manufacturers and original equipment manufacturers. The company's offerings include processor cores, development tools, and application libraries, enabling clients to create programmable integrated circuits for imaging, video, and wireless communication applications. With offices in Eindhoven (Netherlands), San Jose (USA), Tokyo (Japan), Seoul (South Korea), and Bangalore (India), Silicon Hive operates independently since 2007.

ExtendMedia specializes in software and media services that assist content providers and distributors in creating, delivering, managing, and monetizing online content across various devices. The company's flagship product, OpenCASE, serves as a robust foundation for digital media businesses, enabling efficient integration with existing systems and automating large-scale content delivery processes. With over 16 years of experience, ExtendMedia has collaborated with leading communications and media companies, embedding its extensive industry knowledge into OpenCASE. This software not only enhances operational efficiency but also supports diverse business models, making it a valuable tool for media companies and network operators managing digital video content.

Azea Networks Limited, provides world-class submarine optical networking solutions Azea Networks provides world-class submarine optical networking solutions that allow operators to exploit the full potential of their existing cable assets. Azea is uniquely focused on delivering substantial, and cost effective, capacity gains over existing undersea systems. The Azea team combines extensive optical engineering experience in characterisation, system design, modelling and product implementation to provide technologies and services that are a compelling alternative to the cost and risk of deploying new submarine cable systems. Azea’s head office is in London, with manufacturing in Scotland and a number of regional support offices.

Cambridge Broadband Networks Limited, established in 1999 and based in Cambridge, United Kingdom, specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers globally. The company’s flagship product, VectaStar, is a multipoint microwave platform that offers mobile backhaul and enterprise access solutions, including VectaStar Gigabit for macro backhaul and VectaStar Metro for multipoint microwave backhaul. Additionally, VectaStar includes a Radio Controller for enhanced network performance. Cambridge Broadband also provides a comprehensive network management system and various applications to assist with equipment configuration and optimization. The company offers extensive consultancy, training, and support services, allowing network operators to effectively design and implement microwave backhaul networks. By delivering high-quality equipment and services, Cambridge Broadband aims to enhance networking capability and efficiency to address the demands of increasing mobile data traffic.

Hymite is a venture funded product company bringing to market the next generation packaging platform for use with High Power (HP) / Ultra-high Brightness (UHB) LEDs. Hymite's Engineered Silicon (Si) package platform delivers new levels of performance and value to their customers developing products for Solid State Lighting applications.

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drugs to treat autoimmune and central nervous system disorders. The company employs a unique precision deuterium chemistry platform to modify the properties of validated drug molecules, resulting in a diverse pipeline of new chemical entities. Key product candidates include CTP-543, which is in Phase III trials for alopecia areata, and CTP-692, undergoing Phase II trials for schizophrenia. Additionally, AVP-786, a combination therapy for neurologic and psychiatric disorders, is also in Phase III trials. Concert Pharmaceuticals aims to enhance drug safety and efficacy while minimizing research and development risks and costs. Established in 2006 and based in Lexington, Massachusetts, the company has formed strategic collaborations with several pharmaceutical partners to advance its innovative drug development efforts.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. The company focuses on patients suffering from acute renal failure and additional indications where kidney function is compromised. It develops RBI-01, which utilizes physiologically active human renal epithelial cells and administered ex vivo, to replace and maintain severely compromised, or lost kidney functions due to illness, or trauma. The company was founded in 1995 as Nephros Therapeutics, Inc. and changed its name to RenaMed Biologics, Inc. in 2005. RenaMed Biologics, Inc. is based in Lincoln, Rhode Island.